1. Home
  2. LIXT vs SONM Comparison

LIXT vs SONM Comparison

Compare LIXT & SONM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • SONM
  • Stock Information
  • Founded
  • LIXT 2005
  • SONM 1999
  • Country
  • LIXT United States
  • SONM United States
  • Employees
  • LIXT N/A
  • SONM N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • SONM Telecommunications Equipment
  • Sector
  • LIXT Health Care
  • SONM Telecommunications
  • Exchange
  • LIXT Nasdaq
  • SONM Nasdaq
  • Market Cap
  • LIXT 12.4M
  • SONM 12.6M
  • IPO Year
  • LIXT N/A
  • SONM 2019
  • Fundamental
  • Price
  • LIXT $4.47
  • SONM $0.59
  • Analyst Decision
  • LIXT
  • SONM
  • Analyst Count
  • LIXT 0
  • SONM 0
  • Target Price
  • LIXT N/A
  • SONM N/A
  • AVG Volume (30 Days)
  • LIXT 121.5K
  • SONM 239.1K
  • Earning Date
  • LIXT 08-07-2025
  • SONM 08-08-2025
  • Dividend Yield
  • LIXT N/A
  • SONM N/A
  • EPS Growth
  • LIXT N/A
  • SONM N/A
  • EPS
  • LIXT N/A
  • SONM N/A
  • Revenue
  • LIXT N/A
  • SONM $57,917,000.00
  • Revenue This Year
  • LIXT N/A
  • SONM $127.68
  • Revenue Next Year
  • LIXT N/A
  • SONM N/A
  • P/E Ratio
  • LIXT N/A
  • SONM N/A
  • Revenue Growth
  • LIXT N/A
  • SONM N/A
  • 52 Week Low
  • LIXT $0.64
  • SONM $0.52
  • 52 Week High
  • LIXT $5.14
  • SONM $6.38
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 58.29
  • SONM 46.08
  • Support Level
  • LIXT $3.20
  • SONM $0.57
  • Resistance Level
  • LIXT $4.60
  • SONM $0.61
  • Average True Range (ATR)
  • LIXT 0.51
  • SONM 0.03
  • MACD
  • LIXT 0.06
  • SONM 0.02
  • Stochastic Oscillator
  • LIXT 78.53
  • SONM 73.96

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About SONM Sonim Technologies Inc.

Sonim Technologies Inc is a provider of ultra-rugged mobile devices, including phones and accessories designed specifically for task workers physically engaged in their work environments, often in mission-critical roles. The company sells mobile phones, accessories, and solutions to AT&T, T-Mobile, and Verizon in the Canada, and to Bell, Rogers, and Telus and Rogers, Telstra in Australia. The products include rugged mobile phones that can attach to both public and private wireless networks, industrial-grade accessories that meet the requirements of specific applications and software applications, and cloud-based tools that provide management and deployment services to customers. The company generates revenue from discounts, price protection, and customer incentives.

Share on Social Networks: